AZD-0516

N/A

Report date: 2026/05/22 20:01:29
First In Class

Base Information

Drug NameAZD-0516
Drug Alias NameAZD-0516
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Exatecan payload
Mechanisms of ActionAnti-Six-transmembrane epithelial antigen of the prostate 2DNA topoisomerase I inhibitors
TargetsSix-transmembrane epithelial antigen of the prostate 2DNA topoisomerase I
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandItaly +[10] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesBaxter Oncology GmbhAstrazeneca PlcAstrazeneca Ab +[4] 
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A